pseudotumor cerebri: Idiopathic intracranial hypertension is a neurological disorder characterized by isolated increased intracranial pressure manifesting with recurrent and persistent headaches, nausea, vomiting, progressive and transient obstruction of the visual field, papilledema. Visual loss can be irreversible.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
399 |
4. Check minimum number of eventsNone |
399 |
5. Include endpointsNone |
399 |
6. Filter based on genotype QC (FinnGen only) |
382 |
Control definitions (FinnGen only)
- Control exclude
- G6_OTHNEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G93
- Name in latin
- Hypertensio intracranialis benigna
Similar endpoints
↥List of similar endpoints to
Benign intracranial hypertension
based on the number of shared cases.
Similar with more cases:
- Other neurological diseases
- Neurological diseases
- Neurological diseases, wide definition
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1710 | 1314 | 380 |
| Only index persons | 1612 | 1273 | 339 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.04 | 0.01 |
| Only index persons | 0.04 | 0.05 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 31.63 | 30.53 | 35.22 |
| Only index persons | 31.49 | 30.53 | 35.08 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 382 | 316 | 66 |
| Unadjusted period prevalence (%) | 0.10 | 0.11 | 0.03 |
| Median age at first event (years) | 34.40 | 33.14 | 40.42 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 399
- Matched controls
- 3990
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
S01EC01
ATC
acetazolamide; systemic
614.0
307.7
289
17
G93.2
ICD-10 Finland
Benign intracranial hypertension
+∞
307.7
388
*
TAB00
NOMESCO Finland
Lumbar puncture
48.9
288.5
186
70
H47.1
ICD-10 Finland
Papilloedema, unspecified
530.8
211.5
193
7
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
37.5
210.9
142
58
Z01.0
ICD-10 Finland
Examination of eyes and vision
14.8
171.3
238
362
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
19.7
158.9
143
110
CS5Z4
NOMESCO Finland
Specialised imaging for glaucoma
86.5
144.5
77
11
XCK00
NOMESCO Finland
Perimetry
24.2
140.7
109
61
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
38.9
135.1
86
28
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
13.0
118.6
137
154
CS494
NOMESCO Finland
Other visual field testing
42.2
108.8
67
19
R51.80
ICD-10 Finland
Headache
8.1
98.8
220
527
CS434
NOMESCO Finland
Visual field testing with Humphrey automated perimetry
43.3
91.9
56
15
N03AX11
ATC
topiramate; oral
17.3
91.3
81
58
XCW99
NOMESCO Finland
Other investigative procedure of eye
9.7
78.7
107
145
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
17.4
70.6
61
41
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
32.0
65.0
43
15
AA1AD
NOMESCO Finland
CT of head and brain
6.0
59.8
139
326
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
7.3
58.2
100
174
E66.8
ICD-10 Finland
Other obesity
8.1
57.3
87
132
E66.01
ICD-10 Finland
Obesity due to excess calories
6.1
56.8
126
282
C03CA01
ATC
furosemide; systemic
6.7
55.8
106
204
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
606.2
54.9
53
*
H53.1
ICD-10 Finland
Subjective visual disturbances
8.3
52.9
78
114
XCK10
NOMESCO Finland
Photography of fundus of eye
6.0
33.9
66
127
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
6.6
30.5
53
91
E66.9
ICD-10 Finland
Obesity, unspecified
6.6
28.0
48
81
G47.3
ICD-10 Finland
Sleep apnoea
3.8
26.4
99
320
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
6.2
26.4
48
86
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.1
25.5
59
132
G44.2
ICD-10 Finland
Tension-type headache
3.5
25.4
112
402
T82
ICPC
Obesity
5.6
22.5
45
88
G43.0
ICD-10 Finland
Migraine without aura [common migraine]
3.8
22.0
79
246
R42
ICD-10 Finland
Dizziness and giddiness
3.3
21.8
101
371
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.8
21.1
157
750
R4190
NOMESCO Finland
Nutritional therapy
5.6
20.0
40
78
G43.9
ICD-10 Finland
Migraine, unspecified
3.6
19.7
74
237
N03AX12
ATC
[U] gabapentin; oral
3.5
19.4
76
250
G43.3
ICD-10 Finland
Complicated migraine
7.4
19.3
29
42
N02AX02
ATC
tramadol; systemic, rectal
2.6
19.0
162
821
AAF05
NOMESCO Finland
Ventriculoperitoneal shunt
+∞
18.9
18
*
CK2A4
NOMESCO Finland
Autofluorescence imaging of ocular fundus
31.8
18.5
24
8
A02BC02
ATC
pantoprazole; systemic
2.6
18.5
262
1682
XCD10
NOMESCO Finland
Electrophysiological examination of eye
8.0
18.0
25
33
H53.2
ICD-10 Finland
Diplopia
7.0
17.2
27
41
AAF20
NOMESCO Finland
Revision of shunt of ventricle of brain
+∞
16.8
16
*
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.0
16.7
90
356
C09CA06
ATC
candesartan; oral
2.9
16.7
98
407
H02AB06
ATC
prednisolone; systemic
2.4
16.1
194
1133
E23.06
ICD-10 Finland
Empty sella
+∞
15.7
15
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.7
15.5
104
462
CS3P4
NOMESCO Finland
Optic nerve head stereophotography
18.7
15.3
23
13
N03AX16
ATC
[U] pregabalin
2.8
14.9
90
377
XCH00
NOMESCO Finland
Eye pressure measurement
6.7
14.7
24
38
G93.0
ICD-10 Finland
Cerebral cysts
155.5
14.6
15
*
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
155.5
14.6
15
*
N02CC01
ATC
sumatriptan; nasal, systemic, rectal
2.5
14.4
118
574
H47.3
ICD-10 Finland
Other disorders of optic disc
28.4
14.4
19
7
H02AB04
ATC
methylprednisolone; systemic
3.1
13.7
62
221
AAF10
NOMESCO Finland
Lumboperitoneal shunt
+∞
13.6
13
*
KH1AD
NOMESCO Finland
CT of urinary organs
6.2
13.2
23
39
TPH04
NOMESCO Finland
Cathetrisation of vein
2.6
12.9
86
378
R03AC02
ATC
salbutamol; inhalant
2.2
12.8
259
1812
ZXA10
NOMESCO Finland
Bilateral
2.7
12.8
77
321
H47.2
ICD-10 Finland
Optic atrophy
72.2
12.7
14
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.5
12.6
46
143
SPAT1153
SPAT
Removal of sutures
2.4
12.6
114
576
3482A
ICD-9 Finland
Other conditions of brain, Benign intracranial hypertension
+∞
12.6
12
*
3007
Kela drug reimbursment
Erenumab and fremanezumab
6.3
12.2
21
35
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
9.7
12.2
24
26
H93.1
ICD-10 Finland
Tinnitus
4.0
12.1
36
97
H53.4
ICD-10 Finland
Visual field defects
14.0
12.1
20
15
I10
ICD-10 Finland
Essential (primary) hypertension
2.2
12.0
129
700
PA2AD
NOMESCO Finland
CT angiography of brain
31.1
11.7
15
5
N06AX11
ATC
mirtazapine; oral
2.2
11.7
148
856
R51
ICD-10 Finland
Headache
3.2
11.6
48
162
G91.9
ICD-10 Finland
Hydrocephalus, unspecified
+∞
11.5
11
*
CS424
NOMESCO Finland
Visual field testing with Goldmann perimetry
15.6
11.4
18
12
N06AX16
ATC
venlafaxine; oral
2.5
11.3
86
400
N06AX21
ATC
duloxetine; oral
2.7
11.3
66
270
N20.1
ICD-10 Finland
Calculus of ureter
5.8
11.3
21
38
N02BF01
ATC
gabapentin; oral
3.7
11.3
37
107
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
3.0
11.1
52
188
T83
ICPC
Overweight
6.0
11.1
20
35
SPAT1306
SPAT
Counselling and guidance related to nutrition and weight management
2.6
11.0
74
325
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
4.1
10.8
30
77
B03BA03
ATC
hydroxocobalamin; parenteral
5.5
10.7
21
40
E66
ICD-10 Finland
Obesity
3.3
10.6
41
132
SPAT1305
SPAT
Counselling and guidance related to physical exercise
2.9
10.6
52
193
Z01.1
ICD-10 Finland
Examination of ears and hearing
2.7
10.5
60
242
C07AB07
ATC
bisoprolol; oral
2.2
10.5
119
655
G91.8
ICD-10 Finland
Other hydrocephalus
+∞
10.5
10
*
N05BA04
ATC
oxazepam; oral
2.2
10.5
115
625
H53.9
ICD-10 Finland
Visual disturbance, unspecified
4.6
10.4
25
57
G43.1
ICD-10 Finland
Migraine with aura [classical migraine]
2.6
10.4
66
281
M01AE02
ATC
naproxen; oral, rectal
2.1
10.4
262
1923
C08CA01
ATC
amlodipine; oral
2.4
10.2
81
383
A10BA02
ATC
metformin; oral
2.4
10.2
82
390
C10AA05
ATC
atorvastatin; oral
2.4
10.1
77
357
G44.8
ICD-10 Finland
Other specified headache syndromes
9.5
10.1
20
22
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
4.3
10.1
26
63
J45.9
ICD-10 Finland
Asthma, unspecified
2.3
10.0
84
407
J01FF01
ATC
clindamycin; systemic
2.1
9.9
112
614
A02BC05
ATC
esomeprazole; systemic
2.0
9.9
144
868
N02BE01
ATC
paracetamol; systemic, rectal
2.7
9.8
353
2944
A03FA01
ATC
metoclopramide; systemic, rectal
2.3
9.8
90
453
N01
ICPC
Headache
2.2
9.8
98
511
N05CF01
ATC
zopiclone; oral
2.2
9.8
107
578
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.0
9.8
147
895
Z01.8
ICD-10 Finland
Other specified special examinations
2.3
9.8
90
454
N06AB04
ATC
citalopram; systemic
2.3
9.7
87
433
R01AD09
ATC
mometasone; nasal
1.9
9.6
217
1518
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.2
9.5
90
458
N05AH04
ATC
quetiapine; oral
2.1
9.4
106
578
AAF25
NOMESCO Finland
Removal of shunt of ventricle of brain
+∞
9.4
9
*
AAF15
NOMESCO Finland
Ventriculoatrial shunt
+∞
9.4
9
*
SPAT1255
SPAT
Intravenous administration of medicine
3.9
9.3
28
76
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
2.7
9.3
55
226
M03BX02
ATC
tizanidine; oral
2.0
9.3
252
1865
H57.1
ICD-10 Finland
Ocular pain
3.7
9.3
30
86
N02AJ06
ATC
codeine and paracetamol; systemic
1.9
9.1
177
1172
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.4
9.0
23
55
SPAT1263
SPAT
Sampling
1.9
8.9
192
1310
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
4.8
8.9
20
43
N03AX09
ATC
lamotrigine; oral
3.0
8.8
41
148
DFF00
NOMESCO Finland
Pure tone audiometry
3.2
8.8
35
115
JDF11
NOMESCO Finland
Laparoscopic gastric bypass
6.9
8.8
21
32
SPAT1260
SPAT
Consultation of another employee
2.2
8.8
82
415
I67.6
ICD-10 Finland
Nonpyogenic thrombosis of intracranial venous system
51.1
8.7
10
*
WX780
NOMESCO Finland
Remote monitoring CPAP
4.7
8.7
20
44
R33
ICD-10 Finland
Retention of urine
4.7
8.7
20
44
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.9
8.7
42
155
H02AB09
ATC
hydrocortisone; systemic
6.7
8.6
21
33
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
1.9
8.6
166
1091
R53
ICD-10 Finland
Malaise and fatigue
2.0
8.6
114
660
E28.2
ICD-10 Finland
Polycystic ovarian syndrome
3.9
8.5
25
67
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.5
8.5
57
249
OAB72
NOMESCO Finland
Weight control and weight loss guidance
11.1
8.4
15
14
205
Kela drug reimbursment
Chronic hypertension
2.9
8.3
41
153
R01AD08
ATC
fluticasone; nasal
1.9
8.3
135
837
SPAT1249
SPAT
Treatment-related counselling outside office
1.8
8.2
187
1290
C09AA05
ATC
ramipril; oral
2.7
8.1
46
185
N89
ICPC
Migraine
2.8
8.1
43
167
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
2.6
7.9
47
193
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.8
7.9
175
1193
G56.0
ICD-10 Finland
Carpal tunnel syndrome
2.4
7.8
55
245
F33.9
ICD-10 Finland
Recurrent depressive disorder, unspecified
3.0
7.8
36
129
C07AA05
ATC
propranolol; systemic
2.0
7.8
109
639
SPAT1229
SPAT
Assessment of need for aid
4.5
7.8
19
44
SPAT1310
SPAT
Counselling related to known health issue
1.9
7.8
149
970
AAA27
NOMESCO Finland
Insertion of intracerebral pressure monitoring device
45.9
7.7
9
*
M03BC01
ATC
orphenadrine (citrate); systemic
2.0
7.7
102
586
N06AA09
ATC
amitriptyline; systemic
3.2
7.6
31
103
SPAT1301
SPAT
No procedures
1.9
7.6
129
806
G43.2
ICD-10 Finland
Status migrainosus
25.6
7.6
10
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.1
7.6
32
109
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
7.3
7.6
17
24
WX110
NOMESCO Finland
Infiltration anesthesia
2.0
7.4
314
2588
XCW12
NOMESCO Finland
Assessment of colour vision
81.5
7.4
8
*
J35.1
ICD-10 Finland
Hypertrophy of tonsils
3.6
7.4
24
69
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.5
7.3
49
213
G97.1
ICD-10 Finland
Other reaction to spinal and lumbar puncture
+∞
7.3
7
*
R07.4
ICD-10 Finland
Chest pain, unspecified
2.1
7.3
83
451
N06AX26
ATC
vortioxetine; oral
2.5
7.3
50
220
R03BA05
ATC
fluticasone; inhalant
2.0
7.3
89
497
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
16.1
7.3
11
7
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
16.1
7.3
11
7
Z3229
NOMESCO Finland
Other healthcare associate professional
2.9
7.3
34
123
C09CA01
ATC
losartan; oral
2.3
7.3
57
267
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
2.4
7.1
49
216
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.8
7.1
129
821
R06.0
ICD-10 Finland
Dyspnoea
2.0
7.1
91
516
WX725
NOMESCO Finland
Noninvasive ventilation
3.5
7.1
24
71
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
2.4
7.0
48
211
M54.5
ICD-10 Finland
Low back pain
1.8
7.0
153
1029
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
3.3
7.0
26
82
N06AB06
ATC
sertraline; oral
2.1
6.8
71
373
A04AA01
ATC
ondansetron; systemic, rectal
2.9
6.7
31
111
R5140
NOMESCO Finland
Monitoring the use of the aid
2.9
6.7
32
117
W00
ICD-10 Finland
Fall on same level involving ice and snow
2.4
6.7
47
209
CS2P4
NOMESCO Finland
Optic nerve head imaging
23.0
6.7
9
*
G04CA02
ATC
tamsulosin; oral
2.8
6.7
33
123
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.3
6.6
52
243
A02BC01
ATC
omeprazole; systemic
1.9
6.6
99
591
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.8
6.6
144
965
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
1.8
6.6
153
1044
UKC02
NOMESCO Finland
Cystoscopy
2.7
6.6
37
148
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.3
6.6
53
251
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.9
6.5
98
586
WX720
NOMESCO Finland
Own respiration
3.5
6.4
22
66
N02CC06
ATC
eletriptan; oral
2.9
6.3
29
104
N02CD02
ATC
galcanezumab; parenteral
18.4
6.3
9
5
H03AA01
ATC
levothyroxine sodium; systemic
1.9
6.3
91
537
PA6CG
NOMESCO Finland
Extensive MRI examination of neck vasculature with high intensity magnet
+∞
6.3
6
*
G93.1
ICD-10 Finland
Anoxic brain damage, not elsewhere classified
+∞
6.3
6
*
AA7AA
NOMESCO Finland
Liquor cerebri shunt X-ray examinatin without contrast
+∞
6.3
6
*
G91.0
ICD-10 Finland
Communicating hydrocephalus
+∞
6.3
6
*
SFA10
NOMESCO Finland
One-surface restoration
1.7
6.2
249
1961
M75.1
ICD-10 Finland
Rotator cuff syndrome
2.0
6.2
74
408
M54.4
ICD-10 Finland
Lumbago with sciatica
2.0
6.2
74
408
SPAT1312
SPAT
General health counselling
1.7
6.2
156
1085
R06AE07
ATC
cetirizine; oral
1.7
6.2
195
1441
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.3
6.2
48
224
E66.00
ICD-10 Finland
Metabolic syndrome
3.3
6.1
23
73
N03AF02
ATC
oxcarbazepine; oral
3.7
6.1
19
53
PA6BG
NOMESCO Finland
MRI examination of neck vasculature with high intensity magnet
12.8
6.1
10
8
R50.9
ICD-10 Finland
Fever, unspecified
2.0
6.1
66
352
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.9
6.0
28
101
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
161
58
45.86
251.23
1.4
1.3
175.94
29.31
e6/l
1.41
141
49
161
58
45.86
251.23
1.4
1.3
9.35
4.00
e6/l
0.53
135
47
70
13
65.09
125.33
1.1
1.4
1.56
1.81
mmol/l
0.69
65
13
78
28
34.38
118.45
1.1
1.1
—
—
—
0
0
78
28
34.38
118.45
1.1
1.1
—
—
—
0
0
70
18
46.95
116.70
1.2
1.1
1.11
1.05
u/l
—
35
10
75
26
35.29
115.06
1.2
1.2
47.84
31.45
mg/l
0.36
65
20
74
27
33.42
111.60
1.1
1.1
—
—
—
0
0
70
24
35.16
107.57
1.1
1.0
—
—
—
0
0
133
272
6.83
66.77
2.4
1.9
373.20
388.88
nmol/l
0.32
126
248
219
867
4.38
47.38
8.4
7.1
1.07
1.09
inr
0.14
70
302
101
223
5.73
45.45
2.3
2.2
10.24
10.45
g/l
0.26
87
204
92
187
6.09
45.24
4.7
4.8
5.51
5.79
kpa
2.01
92
182
91
187
6.01
44.18
4.7
4.8
-0.46
1.78
mmol/l
3.17
52
148
43
36
13.27
43.49
1.7
3.9
21.12
25.76
mu/l
0.40
43
36
227
972
4.10
42.87
5.4
4.6
36.84
37.28
g/l
0.68
217
913
246
1123
4.10
42.11
7.5
6.1
1.21
1.21
mmol/l
1.01
209
970
298
1596
4.43
39.55
6.6
4.5
6.21
6.26
mmol/l
0.13
286
1390
95
226
5.20
38.90
1.3
1.2
—
21.48
—
0
14
223
993
3.82
38.68
8.9
5.9
1.22
1.22
mmol/l
0.03
212
919
65
115
6.56
36.48
1.7
2.0
38.60
39.26
u/l
0.09
59
104
182
736
3.71
35.99
3.2
2.6
25.16
18.75
ng/l
0.33
74
286
160
621
3.63
33.24
2.5
1.9
120.08
285.96
u/l
0.91
155
591
64
140
5.25
28.45
4.1
3.8
-0.31
0.83
mmol/l
0.65
29
100
102
333
3.77
26.87
4.0
3.7
0.84
0.82
mmol/l
1.00
97
317
34
14
26.41
24.81
1.2
1.4
—
—
—
0
0
78
223
4.10
24.68
7.4
7.4
107.29
105.02
mmol/l
4.35
78
223
80
236
3.99
24.21
5.8
4.0
—
—
—
0
0
236
1323
2.92
24.10
5.5
5.2
9.40
10.35
umol/l
0.59
225
1252
63
161
4.46
23.05
5.0
4.1
5.08
4.86
kpa
0.33
63
156
169
841
2.75
20.95
2.7
2.7
2.31
2.34
mmol/l
2.92
155
762
387
3079
9.54
19.45
20.6
8.9
139.89
139.46
mmol/l
4.88
387
2976
304
2140
2.77
17.08
7.7
6.0
77.41
71.92
u/l
1.22
297
2001
56
169
3.69
16.14
10.9
12.1
0.40
0.78
mmol/l
0.26
34
126
37
82
4.87
15.99
5.5
4.5
0.69
0.69
%
0.04
37
82
348
2685
3.32
15.46
5.4
4.1
14.33
14.32
pmol/l
0.03
331
2487
333
2511
2.97
15.37
5.7
4.0
37.48
37.45
mmol/mol
0.02
319
2380
207
1271
2.31
14.96
3.0
2.3
63.54
71.41
nmol/l
5.17
195
1181
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
22
12
19.32
14.85
1.0
1.3
—
—
—
0
0
21
10
22.07
14.81
1.1
1.3
—
—
—
0
0
308
2255
2.60
14.68
4.4
3.5
10.90
8.64
mm/h
3.38
287
2105
136
707
2.40
14.37
2.2
1.7
0.70
0.78
mg/l
0.28
92
498
88
372
2.75
14.31
1.3
1.3
78.59
164.97
iu/ml
1.68
34
154
149
821
2.30
13.64
4.8
2.3
46.99
56.69
u/l
3.69
143
764
176
1053
2.20
13.05
3.5
2.9
25.03
27.66
u/l
0.91
164
1011
50
166
3.30
12.38
4.8
2.8
1.22
1.22
mmol/l
0.02
45
141
352
2846
3.01
12.14
4.7
3.1
5.74
5.57
mmol/l
1.75
331
2642
371
3092
3.85
12.11
6.3
4.7
1.77
1.72
mu/l
0.46
358
2917
98
475
2.41
11.83
1.9
1.6
399.83
51168641.03
pmol/l
1.07
82
428
16
7
23.73
11.65
1.4
2.0
—
—
—
0
0
76
343
2.50
10.63
2.3
1.5
1269.69
1110.62
nmol/l
0.85
65
276
92
455
2.33
10.50
2.8
2.2
6384.17
4420.47
u/l
0.28
30
196
27
67
4.25
10.13
1.6
2.1
11.58
10.66
mg/l
0.25
27
60
249
1827
1.97
9.49
8.9
7.8
4.57
3.93
e9/l
4.59
234
1586
106
581
2.12
9.30
2.7
2.4
324.07
2650.09
umol/l
1.32
95
534
190
1291
1.90
8.95
4.5
3.0
—
—
—
0
0
99
539
2.11
8.79
1.6
1.4
19.60
21.35
nmol/l
0.46
85
478
150
948
1.93
8.77
2.2
1.7
100.17
95.13
pmol/l
0.72
101
538
127
760
1.98
8.70
2.6
2.1
3.37
2.64
mg/l
1.70
117
657
31
96
3.42
8.54
16.7
12.8
94.84
94.61
%
0.10
31
96
145
927
1.89
8.05
4.6
2.9
—
—
—
0
0
138
876
1.88
7.78
4.9
3.3
0.00
0.01
estimate
1.08
61
346
42
165
2.73
7.71
10.0
8.7
7.54
7.19
mmol/l
0.13
42
159
223
1645
1.81
7.66
4.4
3.1
0.00
0.00
estimate
0.50
66
357
376
3330
3.24
7.64
18.5
9.4
13.33
19.04
mg/l
7.97
330
2504
11
6
18.80
7.64
1.2
1.0
—
—
—
0
0
11
6
18.80
7.64
1.2
1.2
—
—
—
0
0
15
18
8.61
7.38
1.3
1.6
—
—
—
0
0
13
12
11.15
7.34
1.0
1.0
—
—
—
0
0
22
60
3.82
7.29
3.9
4.8
60.64
57.88
%
0.47
22
60
278
2210
1.85
7.27
5.6
3.8
1753.83
740.40
e6/l
—
6
25
219
1642
1.74
6.79
5.6
4.2
0.00
0.00
estimate
0.50
62
349
10
6
17.05
6.77
1.1
1.5
—
—
—
0
0
10
6
17.05
6.77
1.1
1.3
—
—
—
0
0
10
6
17.05
6.77
1.1
1.2
—
—
—
0
0
115
717
1.85
6.71
3.4
3.2
7.54
8.42
mmol/l
1.00
105
627
66
344
2.10
6.45
3.4
2.1
2.43
2.51
g/l
0.55
57
316
20
56
3.71
6.40
1.9
1.4
—
—
—
0
0
90
526
1.92
6.39
4.8
4.3
21.33
12.35
mg/mmol
0.31
56
351
337
2900
2.04
6.33
13.7
7.7
94.75
97.31
ml/min/173m2
1.24
301
2244
219
1666
1.70
6.24
4.5
3.1
0.00
0.00
estimate
-0.00
63
339
328
2802
1.96
6.21
3.9
2.9
1.42
1.18
mmol/l
7.31
311
2650
59
299
2.14
6.19
3.6
2.3
22.17
24.30
%
0.62
44
260
70
379
2.03
6.17
2.6
2.2
2.41
2.40
mmol/l
0.07
61
331
63
331
2.07
6.02
2.0
1.7
—
—
—
0
0
16
40
4.13
5.95
1.8
2.2
—
—
—
0
0
20
59
3.52
5.94
3.5
4.4
4.01
4.59
e9/l
0.59
20
59
209
1586
1.67
5.89
7.4
5.1
59.72
56.08
%
6.10
203
1503
69
379
1.99
5.84
4.0
3.0
1334.97
719.83
ng/l
0.37
48
286
10
9
11.36
5.82
1.0
1.0
—
—
—
0
0
338
2942
1.97
5.69
4.2
3.1
1.29
1.49
mmol/l
19.79
323
2801
11
13
8.66
5.59
1.7
8.2
31.40
269.00
umol/l
—
5
8
279
2301
1.71
5.56
3.8
2.7
35.29
32.14
u/l
0.63
265
2213
341
2985
1.98
5.53
4.5
3.3
2.89
2.81
mmol/l
1.04
322
2830
29
112
2.71
5.52
1.2
1.2
—
—
—
0
0
29
112
2.71
5.52
1.3
1.4
—
—
—
0
0
11
14
8.04
5.37
1.1
1.7
—
—
—
0
0
142
993
1.67
5.36
1.4
1.3
2.18
1.83
u/ml
0.08
41
273
20
65
3.19
5.14
1.7
1.4
273.27
334.48
ug/g
0.50
11
34
109
719
1.71
5.09
4.3
3.0
1.01
1.02
kg/l
0.37
13
99
67
383
1.90
5.02
3.6
2.2
12.91
14.60
umol/l
1.18
56
351
93
589
1.75
5.01
1.3
1.3
13.44
19.47
iu/ml
0.94
21
182
15
432
0.32
4.89
1.4
1.5
—
—
—
0
0
110
735
1.69
4.87
4.3
2.7
0.13
0.26
e6/l
1.31
96
538
46
233
2.10
4.83
3.3
2.6
—
—
—
0
0
335
2956
1.83
4.73
4.3
3.1
4.56
4.68
mmol/l
1.56
319
2817
67
392
1.85
4.67
4.1
2.6
35.17
291.54
ng/l
2.44
29
192
17
53
3.31
4.67
1.1
1.3
—
—
—
0
0
16
48
3.43
4.65
1.0
1.2
—
—
—
0
0
7
5
14.21
4.59
1.4
2.4
—
—
—
0
0
12
23
5.34
4.49
1.1
1.1
1495.75
1362.22
miu/ml
0.14
12
23
40
735
0.49
4.43
1.3
1.5
—
—
—
0
0
9
12
7.64
4.37
1.0
1.2
—
—
—
0
0
24
97
2.57
4.21
2.5
2.3
—
—
—
0
0
13
30
4.44
4.16
1.1
1.1
—
—
—
0
0
53
301
1.88
4.05
1.4
1.4
11.65
18.69
iu/l
1.62
48
250
14
36
3.99
4.03
1.1
1.2
—
—
nmol/l
—
0
0
47
257
1.94
4.02
3.4
3.6
4.66
4.67
pmol/l
0.03
37
232
31
146
2.22
3.92
1.2
1.6
—
—
—
0
0
16
54
3.04
3.89
1.1
1.5
—
—
—
0
0
13
33
4.04
3.83
2.2
2.8
1.81
1.57
%
0.09
13
28
45
247
1.93
3.81
1.4
1.3
697.68
194.51
u/ml
0.46
40
229
26
116
2.33
3.73
5.5
3.0
0.14
0.12
e6/l
0.08
26
111
394
3792
4.11
3.64
27.6
14.2
40.23
39.97
%
0.35
375
3634
17
400
0.40
3.59
1.5
1.4
—
—
—
0
0
41
223
1.93
3.57
2.2
1.5
—
—
—
0
0
28
132
2.21
3.55
1.8
1.4
—
—
—
0
0
19
76
2.58
3.43
1.2
1.0
—
—
—
0
0
11
27
4.16
3.42
1.4
1.3
—
—
—
0
0
16
59
2.78
3.36
9.8
2.4
1.33
1.01
nmol/l
0.68
16
52
18
402
0.42
3.35
1.4
1.4
—
—
—
0
0
18
401
0.42
3.33
1.4
1.4
—
—
—
0
0
18
401
0.42
3.33
1.4
1.4
—
—
—
0
0
25
118
2.19
3.17
1.8
1.7
1.28
1.18
g/l
0.94
25
113
85
588
1.57
3.17
1.2
1.2
1.22
8.48
u/ml
3.60
25
243
39
218
1.87
3.15
2.2
1.5
—
—
—
0
0
8
16
5.08
3.06
2.3
2.6
39325.00
31987.81
ug/l
—
8
16
6
8
7.59
3.06
1.2
1.0
8.83
38.09
u/l
—
6
8
6
8
7.59
3.06
1.2
1.0
71.00
76.39
u/l
—
6
8
13
45
2.95
3.05
1.0
1.1
—
—
—
0
0
63
409
1.64
3.05
2.7
2.3
0.81
0.76
e6/l
0.07
43
221
32
171
1.95
2.96
1.7
2.0
59.58
81.22
ml/min/173m2
1.39
12
63
11
32
3.50
2.92
1.3
1.3
—
—
—
0
0
193
1592
1.41
2.91
2.8
2.5
—
—
—
0
0
44
264
1.75
2.84
4.0
3.0
28.69
31.77
%
1.53
36
197
36
205
1.83
2.76
1.4
1.4
—
—
—
0
0
6
10
6.07
2.70
1.5
2.1
0.97
1.82
ug/l
—
6
10
6
10
6.07
2.70
1.5
1.3
102.67
66.10
nmol/24h
—
6
10
5
7
7.22
2.55
1.0
1.3
—
—
—
0
0
6
11
5.52
2.55
1.0
1.2
—
—
—
0
0
222
1906
1.37
2.49
4.2
2.9
75.85
61.20
ug/l
1.34
210
1788
6
12
5.06
2.41
1.2
3.0
361.33
392.92
u/ml
—
6
12
9
27
3.39
2.40
1.4
1.4
—
—
—
0
0
44
278
1.65
2.38
1.0
1.0
—
—
—
0
0
8
22
3.69
2.37
2.4
2.7
—
—
—
0
0
10
33
3.08
2.37
1.2
1.2
—
—
—
0
0
19
91
2.14
2.37
1.6
1.3
184.38
210.28
u/ml
0.22
13
59
10
34
2.99
2.29
1.2
1.2
—
—
—
0
0
10
34
2.99
2.29
1.2
1.2
—
—
—
0
0
10
34
2.99
2.29
1.2
1.2
—
—
—
0
0
10
34
2.99
2.29
1.2
1.2
—
—
—
0
0
10
34
2.99
2.29
1.2
1.2
—
—
—
0
0
12
51
2.39
1.97
1.2
1.3
—
—
—
0
0
14
64
2.23
1.96
1.4
1.3
—
1.72
—
0
5
47
320
1.53
1.90
3.2
2.8
5.03
5.25
umol/l
0.12
38
256
8
28
2.89
1.87
1.3
1.5
—
—
—
0
0
18
94
1.96
1.83
1.5
1.3
—
—
—
0
0
8
30
2.70
1.73
1.4
14.3
19.85
6.34
mmol/l
—
8
22
8
30
2.70
1.73
1.6
1.5
—
—
—
0
0
14
68
2.10
1.72
1.1
1.1
0.96
14.18
iu/ml
—
7
22
6
19
3.19
1.66
1.0
1.0
—
—
—
0
0
5
14
3.60
1.62
1.2
1.1
—
—
—
0
0
5
14
3.60
1.62
1.6
1.4
—
—
—
0
0
54
392
1.44
1.61
4.0
2.5
2.67
4.11
e6/l
0.91
33
204
13
63
2.10
1.61
1.0
1.0
—
—
—
0
0
14
70
2.04
1.61
3.8
3.4
14.34
26.19
mg/l
—
9
49
88
697
1.34
1.57
1.9
1.6
1.47
1.36
mmol/l
0.71
78
614
94
758
1.31
1.48
2.4
1.8
—
—
—
0
0
28
420
0.64
1.47
1.4
1.4
—
—
—
0
0
7
28
2.53
1.46
1.3
1.3
—
—
—
0
0
7
28
2.53
1.46
1.3
1.3
—
—
—
0
0
22
133
1.69
1.46
1.2
1.1
2.99
4.03
u/ml
—
10
72
13
67
1.97
1.40
1.2
1.1
—
—
—
0
0
11
53
2.11
1.39
1.6
1.4
—
—
—
0
0
8
158
0.50
1.28
1.6
1.5
—
—
—
0
0
10
49
2.07
1.23
1.1
1.8
—
—
—
0
0
141
1222
1.24
1.22
2.1
1.7
—
—
—
0
0
24
354
0.66
1.19
1.4
1.6
—
—
—
0
0
8
38
2.13
1.19
1.0
1.1
—
—
—
0
0
18
110
1.67
1.17
1.1
1.1
1.84
1.73
u/ml
—
9
55
63
497
1.32
1.17
2.2
1.7
1.32
1.30
%
0.07
56
459
8
39
2.07
1.16
1.3
1.4
—
—
—
0
0
8
39
2.07
1.16
1.3
1.4
—
—
—
0
0
10
51
1.99
1.12
1.8
2.2
—
—
—
0
0
11
59
1.89
1.08
1.4
1.2
—
—
—
0
0
5
22
2.29
1.03
1.4
3.2
17.00
26.04
u/ml
—
5
22
6
27
2.24
0.94
1.0
1.5
—
—
—
0
0
10
55
1.84
0.93
1.7
1.4
—
—
—
0
0
8
42
1.92
0.89
1.3
1.4
—
—
—
0
0
13
80
1.65
0.85
1.2
1.1
—
10.97
—
0
7
16
105
1.55
0.83
1.3
1.2
—
—
—
0
0
16
105
1.55
0.83
1.3
1.2
—
—
—
0
0
6
32
1.89
0.82
1.0
1.1
—
—
—
0
0
19
268
0.69
0.79
1.3
1.5
—
—
—
0
0
11
173
0.63
0.77
1.1
1.4
—
—
—
0
0
6
34
1.78
0.76
1.2
1.5
—
—
—
0
0
7
38
1.86
0.74
1.6
1.2
—
—
—
0
0
23
309
0.73
0.73
1.5
1.7
—
—
—
0
0
7
40
1.76
0.71
1.1
1.4
—
—
—
0
0
14
93
1.52
0.70
1.4
1.9
—
—
—
0
0
7
42
1.68
0.68
1.4
1.9
—
—
—
0
0
12
79
1.54
0.63
1.7
2.3
—
—
—
0
0
5
30
1.67
0.61
1.0
1.7
—
—
—
0
0
40
484
0.81
0.61
1.5
1.4
—
—
—
0
0
5
86
0.58
0.57
1.6
1.5
—
—
—
0
0
19
142
1.35
0.55
2.4
4.3
10.51
7.97
ug/l
0.11
14
109
6
38
1.59
0.54
1.0
1.1
—
—
—
0
0
15
198
0.75
0.46
1.3
1.6
—
—
—
0
0
8
120
0.66
0.46
1.5
1.3
—
—
—
0
0
7
49
1.44
0.46
1.3
1.2
—
—
—
0
0
7
49
1.44
0.46
1.3
1.2
—
—
—
0
0
40
343
1.18
0.42
2.2
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
13
98
1.34
0.38
1.5
1.9
—
—
—
0
0
316
3084
1.12
0.38
4.2
4.1
—
—
—
0
0
6
41
1.47
0.36
1.5
2.6
5.27
100.27
u/ml
—
6
41
30
256
1.19
0.34
1.3
1.3
241.30
266.19
miu/ml
0.09
11
136
34
300
1.15
0.27
1.4
1.3
—
—
—
0
0
8
65
1.24
0.27
1.4
1.2
—
—
—
0
0
114
1083
1.07
0.24
2.3
2.2
—
—
—
0
0
107
1017
1.07
0.22
1.4
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.6
—
—
—
0
0
66
620
1.08
0.19
1.8
1.9
—
—
—
0
0
7
61
1.15
0.17
1.0
1.5
—
—
—
0
0
8
98
0.81
0.14
1.5
1.8
8.06
7.62
mmol/l
—
8
93
17
153
1.12
0.11
1.7
1.7
—
—
—
0
0
21
193
1.09
0.10
2.4
2.1
—
—
—
0
0
82
795
1.04
0.09
2.0
2.0
—
—
—
0
0
20
187
1.07
0.06
2.8
4.1
25.17
21.63
%
—
6
78
11
99
1.11
0.06
1.9
1.4
—
—
—
0
0
16
151
1.06
0.03
1.9
2.3
4.17
4.75
umol/l
0.31
11
111
119
1197
0.99
0.01
2.4
2.3
—
—
—
0
0
14
143
0.98
0.00
2.1
2.6
0.63
0.63
ug/l
—
7
83
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
6
69
0.87
0.00
12.8
1.8
12.97
13.08
%
—
6
69
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
56
0.89
-0.00
1.2
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
9.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
17.29
—
0
7
0
6
0.00
-0.00
0.0
3.2
—
53.25
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint G6_BENINTRAHYP and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have G6_BENINTRAHYP.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: G6_BENINTRAHYP – Benign intracranial hypertension
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data